10x Genomics, Inc.
TXG
$22.37
-$0.25-1.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 642.82M | 641.81M | 644.47M | 624.66M | 610.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 642.82M | 641.81M | 644.47M | 624.66M | 610.79M |
| Cost of Revenue | 198.44M | 199.62M | 196.19M | 197.65M | 196.00M |
| Gross Profit | 444.38M | 442.19M | 448.28M | 427.01M | 414.78M |
| SG&A Expenses | 310.11M | 329.82M | 336.87M | 347.20M | 342.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 743.09M | 775.18M | 787.77M | 805.15M | 802.14M |
| Operating Income | -100.26M | -133.36M | -143.31M | -180.49M | -191.36M |
| Income Before Tax | -39.91M | -73.09M | -79.33M | -153.40M | -177.70M |
| Income Tax Expenses | 3.64M | 3.23M | 5.27M | 3.63M | 4.93M |
| Earnings from Continuing Operations | -43.54 | -76.32 | -84.60 | -157.04 | -182.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.54M | -76.32M | -84.60M | -157.04M | -182.63M |
| EBIT | -100.26M | -133.36M | -143.31M | -180.49M | -191.36M |
| EBITDA | -64.07M | -98.48M | -109.75M | -145.78M | -155.48M |
| EPS Basic | -0.35 | -0.62 | -0.70 | -1.30 | -1.52 |
| Normalized Basic EPS | -0.40 | -0.58 | -0.63 | -0.83 | -0.91 |
| EPS Diluted | -0.35 | -0.62 | -0.70 | -1.30 | -1.52 |
| Normalized Diluted EPS | -0.40 | -0.58 | -0.63 | -0.83 | -0.91 |
| Average Basic Shares Outstanding | 498.94M | 493.46M | 488.69M | 485.00M | 481.79M |
| Average Diluted Shares Outstanding | 499.70M | 494.21M | 489.45M | 485.00M | 481.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |